Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Celularity Inc (CELUW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CELUW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.76 | 52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 |
52 Weeks Range 0.01 - 0.12 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.87 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.77% | Operating Margin (TTM) -52.25% |
Management Effectiveness
Return on Assets (TTM) -17.42% | Return on Equity (TTM) -232.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 11684589 |
Shares Outstanding - | Shares Floating 11684589 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Celularity Inc
Company Overview
History and Background
Celularity Inc. was founded in 2016. It focuses on developing and commercializing cellular medicines and biomaterials.
Core Business Areas
- Allogeneic Cell Therapy: Development of off-the-shelf placental-derived cell therapies for various diseases.
- Biomaterials: Production and distribution of placental-derived biomaterials for surgical applications and wound care.
- Biobanking: Offers placental-derived stem cells and cells for research and therapeutics.
Leadership and Structure
The company is led by a board of directors and an executive team. Key leaders include the CEO and CFO. They are structured around the business segments of cell therapies, biomaterials, and research programs.
Top Products and Market Share
Key Offerings
- CYNK-001: An allogeneic natural killer (NK) cell therapy for hematologic malignancies and solid tumors. Market share data is not readily available. Competitors include Fate Therapeutics (FATE) and Nkarta (NKTX).
- PDA-002: A placental-derived cell therapy for Crohn's disease. Specific market share data is not readily available. Competitors include Takeda Pharmaceutical (TAK) with Entyvio.
- Intercyteu00ae Matrix: A placental-derived biomaterial for surgical applications. Market share data not available. Competitors include Osiris Therapeutics (now part of Smith+Nephew (SNN)).
Market Dynamics
Industry Overview
The cell therapy and regenerative medicine industry is growing rapidly, driven by advances in biotechnology and increasing demand for novel therapies. Competition is intense, with many companies vying for market share.
Positioning
Celularity Inc. is positioned as a leader in placental-derived cell therapies and biomaterials. Its competitive advantage lies in its proprietary platform and access to placental tissue. They are a smaller player in a field dominated by larger pharmaceutical companies
Total Addressable Market (TAM)
The overall market for cell therapies is estimated in the tens of billions of dollars and is expected to grow. Celularity is competing for a part of this market with its existing technology and products.
Upturn SWOT Analysis
Strengths
- Proprietary placental-derived technology platform
- Diverse pipeline of cell therapy and biomaterial products
- Intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources compared to larger competitors
- Clinical trial execution risk
- Reliance on manufacturing partners
- Dependence on regulatory approvals
Opportunities
- Expanding into new therapeutic areas
- Partnering with larger pharmaceutical companies
- Acquiring complementary technologies
- Gaining regulatory approvals for key products
Threats
- Competition from established pharmaceutical companies
- Unfavorable regulatory changes
- Clinical trial failures
- Economic downturns
Competitors and Market Share
Key Competitors
- BMY
- JNJ
- TAK
- CRSP
- FATE
Competitive Landscape
Celularity is a smaller player focusing on placental-derived technologies in a competitive landscape dominated by larger pharma and biotech companies. Their niche may offer unique advantages, but they face financial and market access challenges.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends would be derived from the company's financial statements. Access to this data is needed.
Future Projections: Future growth projections would be based on analyst estimates, requiring specialized financial databases.
Recent Initiatives: Recent initiatives include clinical trial advancements for CYNK-001 and PDA-002, and market expansion of their biomaterials.
Summary
Celularity Inc. is a regenerative medicine company with unique placental-derived technology. While their technology is interesting and may lead to future advancement of allogeneic medicines, they face risks with the competitive landscape dominated by large pharmaceuticals and biotech companies. A challenge will be to secure financial resources to advance its pipeline through clinical trials and regulatory approvals. They must continue to demonstrate the efficacy and safety of its products in order to continue.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (where available)
- Industry Reports
- Analyst Reports (where available)
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share estimates are approximations and may not be precise. Financial data is dependent on available information.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Celularity Inc
Exchange NASDAQ | Headquaters Florham Park, NJ, United States | ||
IPO Launch date 2019-07-19 | Founder, CEO & Chairman Dr. Robert Joseph Hariri M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 123 | Website https://www.celularity.com |
Full time employees 123 | Website https://www.celularity.com | ||
Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. In addition, it produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.